World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
128
Citations
108643
World Ranking
2637
National Ranking
1477

Jeffrey S. Weber publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jeffrey S. Weber sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 598 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jeffrey S. Weber D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jeffrey S. Weber sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 128 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jeffrey S. Weber is affiliated with New York University in the United States and has contributed extensively to the field of medicine, with a primary focus on oncology. Their research spans a range of subfields including molecular biology, immunology, cancer research, and pulmonary and respiratory medicine.

The scientist's recent publications reflect their ongoing work in cancer immunotherapy, particularly in melanoma treatment and immune response. Selected recent papers include:

  • Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study (2024, The Lancet)
  • Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial (2020, The Lancet Oncology)
  • Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma (2021, Journal of Clinical Oncology)
  • Systemic Therapy for Melanoma: ASCO Guideline (2020, Journal of Clinical Oncology)
  • Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies (2021, Nature Reviews Drug Discovery)

Their frequent coauthors include:

  • Paolo A. Ascierto
  • Georgina V. Long
  • James Larkin
  • Iman Osman
  • Omid Hamid

Geographically and institutionally embedded in the United States, Jeffrey S. Weber has published most prolifically in several key journals:

  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • Clinical Cancer Research
  • Cancer Research
  • Regular and Young Investigator Award Abstracts

The main research topics covered in their work include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cutaneous Melanoma Detection and Management
  • Melanoma and MAPK Pathways
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies

Their publications consistently contribute to understanding the mechanisms and treatment options for melanoma and other cancers, often emphasizing immune-based therapies and personalized medicine approaches. The scientist's research outputs are reflected in high citation counts and ongoing collaborations that link clinical oncology, immunotherapy, and translational research.

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

    Jedd D. Wolchok;Axel Hoos;Steven O'Day;Jeffrey S. Weber

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Dirk Schadendorf;F. Stephen Hodi;Caroline Robert;Jeffrey S. Weber

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

    Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

  • Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

    Jeffrey S. Weber;Katharina C. Kähler;Axel Hauschild

  • Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2

    Steven A. Rosenberg;James C. Yang;Suzanne L. Topalian;Douglas J. Schwartzentruber

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.

    Peter P. Lee;Cassian Yee;Peter A. Savage;Lawrence Fong

  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

  • Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

    Steven A. Rosenberg;John R. Yannelli;James C. Yang;Suzanne L. Topalian

  • Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

    Jeffrey S. Weber;F. Stephen Hodi;Jedd D. Wolchok;Suzanne L. Topalian

  • Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Antoni Ribas;Omid Hamid;Adil Daud;F. Stephen Hodi

  • Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

    Morganna Freeman-Keller;Youngchul Kim;Heather Cronin;Allison Richards

Frequent Co-Authors

Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
F. Stephen Hodi
F. Stephen Hodi Harvard University
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Caroline Robert
Caroline Robert University of Paris-Saclay
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Adil Daud
Adil Daud University of California, San Francisco
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Vernon K. Sondak
Vernon K. Sondak University of South Florida
Richard F. Kefford
Richard F. Kefford Macquarie University
Mario Sznol
Mario Sznol Yale University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean attending medical school. There are flexible alternatives to get started or advance in healthcare, especially with today’s online degree options. Many professionals begin as licensed practical nurses. If you’re looking for an entry point, consider enrolling in a lpn program online to fast-track your way into the field.

If you’re already an RN and want to earn your bachelor’s, there are now rn to bsn programs no clinicals, allowing you to further your education from home with minimal on-site requirements.

For nurses aiming for the highest level of clinical practice, accelerated dnp programs can help you earn a doctorate quickly. Additionally, some online dnp programs without dissertation make it more accessible for working nurses to advance without the challenge of lengthy research projects.

Each pathway provides unique opportunities, letting you tailor your medical career to your goals, background, and schedule.

Best Scientists Citing Jeffrey S. Weber

Trending Scientists

Recently Published Articles